TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cerebral metastases meeting the following criteria:~  * One to three presumed brain metastases~ * Metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate)~    * Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s)~ * Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days~ * Lesions must not be within 5 mm of the optic chiasm or within the brainstem~* Eligibility for treatment with gamma knife or linear accelerator-based radiosurgery confirmed by a radiation oncologist~* No primary germ cell tumor, small cell carcinoma, or lymphoma~* No leptomeningeal metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* ECOG performance status 0-2~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~  * Male patients must continue to use contraception for 3 months after the completion of radiotherapy~* No pacemaker or other MRI-incompatible metal in the body~* No known allergy to gadolinium~PRIOR CONCURRENT THERAPY:~* More than 7 days since prior and no concurrent chemotherapy~* No prior cranial radiotherapy~* No prior resection of cerebral metastases~* Concurrent hormonal agents, steroids, and/or anticonvulsants allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients undergo stereotactic radiosurgery (SRS)
- Arm II (Type: EXPERIMENTAL): Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Roflumilast in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Chronic stable plaque psoriasis (min duration 6 months)~* PASI \>8~* Body mass index (BMI) \> 20 kg/m2~* Candidate for systemic treatment of psoriasis~* Negative pregnancy test (only women)~* Safe anticonception during entire study and at least 1 week after end of treatment (\~5 times plasma half-life of roflumilast) (only applying for fertile women)~Exclusion Criteria:~* Severe immunological disease, e.g. HIV, systemic lupus, and systemic sclerosis~* Current tuberculosis~* Current viral hepatitis~* Heart failure (NYHA III-IV)~* Moderate or severe liver failure (Child-Pugh B-C)~* Current or former malignancy (basal cell carcinoma excluded)~* Current or former depression with suicidal ideation~* Topical therapy for psoriasis during within 2 of randomization or during study~* Systemic therapy for psoriasis or psoriatic arthritis within 4 weeks of randomization or during study~* Treatment with theophylline, phenobarbital, carbamazepine, or phenytoin~* Confirmed pregnancy~* Planned pregnancy within 6 months~* Breast feeding~* Blood donation during study~* Inability to complete study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): Roflumilast 500 microgram daily (capsule)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (capsule)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected individual.~* 18 years and older.~* Taking tenofovir.~* Blood drawn during regular clinic visit.~Exclusion Criteria:~* Refusal to participate.~* Pregnancy.~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive~* Currently receiving ART~* Current viral load (VL) ˃200 copies/ml~* Report drinking at hazardous levels, operationalized as exceeding 14 standard drinks per week for men or exceeding 7 standard drinks per week for women, or reported use of illicit drugs exclusive of marijuana or illicit use of prescription opioids within the past 3 months.~Exclusion Criteria:~None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Site 1 Immediate PLUS intervention (Type: EXPERIMENTAL): Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
- Wait-list PLUS condition (Type: ACTIVE_COMPARATOR): Received the PLUS intervention at 12 months post baseline
- Site 2 Immediate PLUS intervention (Type: EXPERIMENTAL): Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
- Site 3 Immediate PLUS intervention (Type: EXPERIMENTAL): Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nonconvulsive Electrotherapy: a Proof-of-concept Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 years and older meeting structured clinical interview for the DSM IV (SCID) criteria for unipolar major depressive disorder, bipolar disorder, or schizoaffective disorder.~2. Subjects of child-bearing potential must agree to have a pregnancy test prior to enrollment and agree to use a reliable method of birth-control during the study.~3. Willingness and ability to provide informed consent as determined by satisfactorily completing the study-specific Evaluation to Sign Consent Form Test.~4. Baseline score ≥ 16 on the 21-item version of the Hamilton Depression Rating Scale (HAMD-21) for unipolar depression, the Bipolar Depression Rating Scale (BDRS) for bipolar depression, or the Young Mania rating scale (YMRS) for mania.~5. Willingness to allow the Principal Investigator to discuss study participation with treating psychiatrist~6. Taking the same regimen of psychiatric medications with no changes for at least one month prior to NET treatment and willingness to not have any medication changes during NET treatment.~7. Currently an outpatient.~8. History of or currently refusing ECT due to experience of or anticipation of adverse effects.~Exclusion Criteria:~1. Pregnancy.~2. Use of any investigational drugs within 30 days of baseline or at any time during the study.~3. Ongoing substance abuse or dependence.~4. Current suicidal ideas.~5. Presence of any condition that would contraindicate ECT or bifrontal electrode placement.~6. Medical or neurologic condition etiologically related to mood disorder.~7. History of coronary artery disease or cardiac arrhythmia.~8. History of serious, potentially life-threatening reaction to anesthesia.~9. For individuals who need to have brain imaging, presence of metal in the body that would make a head MRI unsafe.~10. For individuals who need to have brain imaging, history of claustrophobia or anxiety associated with previous MRI.~11. Allergy or adverse reaction to methohexital or succinylcholine.~12. Epilepsy or seizure disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nonconvulsive electrotherapy (Type: EXPERIMENTAL): Open label single arm study of nonconvulsive electrotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medical Management of Sleep Disturbance During Opioid Tapering

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 years old and above~* Meets Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for OUD with evidence of physical dependence on opioids, and seeking treatment to stop using illicit opioids.~* Provides a urine sample that tests positive for opioids.~* Willing to comply with the study protocol.~* Have no clinically significant chronic medical or surgical disorders or conditions that are judged by the investigators to prevent participation.~Exclusion Criteria:~* Seeking or currently enrolled in methadone or buprenorphine maintenance treatment for OUD~* Pregnant or breast feeding~* Have evidence of physical dependence on alcohol or benzodiazepines that requires medical detoxification~* Have a known allergy to the study medications~* Past 30-day prescribed use of suvorexant or benzodiazepines for the indication of insomnia~* Current use of a Selective Serotonin Reuptake Inhibitor (SSRI) or Monoamine oxidase (MAO) inhibitor for depression or insomnia, or other medications that are contraindicated with suvorexant~* Current narcolepsy, restless leg syndrome or sleep paralysis~* High risk for current sleep apnea~* Current major depressive disorder~* Past year suicidal behavior~* Severe hepatic or renal impairment~  * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \>3x ULN~ * Total bilirubin \>2x Upper Limit of Normal (ULN)~ * Creatinine \>1.5x ULN~* Have circumstances that would interfere with study participation (e.g., impending jail)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo sleep medication (Placebo oral capsule)
- Low Dose Suvorexant (Type: ACTIVE_COMPARATOR): Low dose sleep medication
- High Dose Suvorexant (Type: ACTIVE_COMPARATOR): High dose sleep medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 480 Biomedical Sinus Drug Depot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CS.~* Female study subjects of child-bearing potential must have a negative pregnancy test and must agree to not become pregnant during the course of the study.~* The study subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ethics committee of the respective clinical site.~* The study subject agrees to comply with all study requirements~Exclusion Criteria:~* Known history of intolerance to corticosteroids.~* Oral-steroid dependent condition.~* Having had corticosteroids with potential systemic effect (e.g., oral, parenteral, or high dose topical) 1 month prior to screening visit.~* Subjects with acute or chronic intracranial or orbital complications of chronic rhinosinusitis (e.g., brain abscess, related problems with eyes or central nervous system).~* Known history of hypothalamic pituitary adrenal (HPA) axial dysfunction or having morning serum cortisol level at screening outside of normal range.~* Previous pituitary or adrenal surgery.~* History or diagnosis (in either eye) of glaucoma, ocular hypertension, or cataracts.~* Recent participation in another clinical trial within 1 month of screening visit.~* Subjects currently participating in an investigational drug or device study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 480 Mometasone Furoate Sinus Drug Depot (Type: EXPERIMENTAL): 480 Mometasone Furoate Sinus Drug Depot

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 90 years of age, inclusive.~* Diagnosed with primary episode or first relapse of moderate C. difficile infection.~Received ≤24 hours of therapy effective for C. difficile infection prior to enrollment.~Exclusion Criteria:~* Severe C. difficile infection~* Expected to require more than 10 days of C. difficile infection treatment.~* More than one prior episode of C. difficile infection within the prior 3 months.~* Use of anti-peristaltic drugs (including tincture of opium, metoclopramide, loperamide),, cholestyramine, or colestipol~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- LFF571 (POC) (Type: EXPERIMENTAL): None
- Vancomycin (POC) (Type: ACTIVE_COMPARATOR): None
- LFF571 Dose level 1 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 2 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 3 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 4 (cohort 2) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Right Ventricular Pacing Using the Feature Ventricular Intrinsic Preference (VIP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has been implanted with dual chamber SJM Victory® device with VIP™ for 1 month (± 2 weeks).~* At the time of pacemaker implant, VIP™ is programmed OFF.~* At the time of enrollment, patient is paced in the RV ≤ 60% of the time.~* Patient is medically stable.~Exclusion Criteria:~* Patient has evidence of complete AV block, such that ventricular pacing would be required as part of the patient's routine management.~* Patient is indicated for AF Suppression.~* Patient has persistent or chronic atrial fibrillation.~* Patient is unable to comply with the follow-up visits due to geographical, psychological, or any other reasons.~* Patient is currently participating in another device research study.~* Patient is younger than 18 years of age.~* Patient is pregnant.~* Patients life expectancy is less than 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- VIP On, Then VIP Off (Type: EXPERIMENTAL): Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
- VIP Off, Then VIP On (Type: EXPERIMENTAL): Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CBT for Adherence and Depression in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of type 2 diabetes that is poorly controlled despite treatment with an oral hypoglycemic, insulin, or both~* Diagnosis of major depression or dysthymia, or current subclinical symptoms of depression in spite of prescription of an antidepressant~* If on an antidepressant, oral hypoglycemic medication, or insulin, must have been on a stable dose for the preceding two months~Exclusion Criteria:~* Active untreated major mental illness (e.g., untreated psychosis), bipolar disorder, eating disorder, mental retardation, or dementia~* Experiencing suicidal thoughts~* History of or currently receiving CBT for depression~* Uses an insulin pump

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Enhanced treatment as usual (Type: ACTIVE_COMPARATOR): Enhanced treatment as usual plus single-session life-steps treatment
- CBT-AD (Type: EXPERIMENTAL): Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ICD-10-CM diagnosis code of D68.32 (Hemorrhagic disorder due to extrinsic circulating anticoagulants) as part of an inpatient admission~* Taking either an oral FXa inhibitor or enoxaparin at the time of hospitalization for their bleeding event~* Treated with either andexanet alfa or 4F-PCC during the hospitalization for their bleeding event~* Had documented discharge disposition~Exclusion Criteria:~* Less than 18 years old~* Treated with both andexanet alfa and 4F-PCC during the hospitalization for their bleeding event

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Patients hospitalized for an anticoagulation-related major bleed (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Relapsed/refractory multiple myeloma~* Progressed or are intolerant of established therapies including proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody~* Performance Status of 0- 1 ( Performance Score 2 is permitted only if due to underlying myeloma)~* Adequate bone marrow, hematological, kidney and liver function~* Resolved acute effects of any prior therapy to baseline severity~* Not pregnant~Exclusion Criteria:~* Recent history of other malignancies~* History of active autoimmune disorders~* Any form of primary immunodeficiency~* Active and clinically significant bacterial, fungal, or viral infection~* Evidence of active mucosal or internal bleeding~* History of severe immune-mediated adverse event with prior immunomodulatory treatment~* Major surgery within 4 weeks of study treatment start~* Radiation therapy within 2 weeks of study treatment start~* History of stem cell transplant (autologous or allogeneic) within 100 days prior to study enrollment~* Donor Lymphocyte Infusion (DLI) within 30 days prior to study entry~* Less than 30 days since last dose of antibody based therapies or less than 5 half-lives since last dose of previous therapy~* Requirement for systemic immune suppressive medication except as permitted in the protocol~* Current requirement for chronic blood product support

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-06863135 (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody
- PF-06863135 + dexamethasone (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + dexamethasone
- PF-06863135 + lenalidomide (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + lenalidomide
- PF-06863135 + pomalidomide (Type: EXPERIMENTAL): BCMA-CD3 bispecific antibody + pomalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete